MMWR - Meningococcal Vaccination: Recommendations of …

1 Recommendations and Reports / Vol. 69 / No. 9 September 25, 2020 Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, Department of Health and Human ServicesCenters for disease control and PreventionMorbidity and Mortality Weekly ReportRecommendations and ReportsThe MMWR series of publications is published by the center for Surveillance, Epidemiology, and Laboratory Services, centers for disease control and prevention (CDC), Department of Health and Human Services, Atlanta, GA citation: [Author names; first three, then et al.]

2 , if more than six.] [Title]. MMWR Recomm Rep 2020;69(No. RR-#):[inclusive page numbers].Centers for disease control and PreventionRobert R. Redfield, MD, DirectorAnne Schuchat, MD, Principal Deputy DirectorChesley L. Richards, MD, MPH, Deputy Director for Public Health Science and SurveillanceRebecca Bunnell, PhD, MEd, Director, Office of ScienceArlene Greenspan, PhD, Acting Director, Office of Science Quality, Office of ScienceMichael F. Iademarco, MD, MPH, Director, center for Surveillance, Epidemiology, and Laboratory Services MMWR Editorial and Production Staff (Serials)Charlotte K.

3 Kent, PhD, MPH, Editor in Chief Christine G. Casey, MD, EditorMary Dott, MD, MPH, Online EditorTerisa F. Rutledge, Managing EditorDavid C. Johnson, Lead Technical Writer-EditorMarella Meadows, Project EditorMartha F. Boyd, Lead Visual Information SpecialistAlexander J. Gottardy, Maureen A. Leahy, Julia C. Martinroe, Stephen R. Spriggs, Tong Yang,Visual Information SpecialistsQuang M. Doan, MBA, Phyllis H. King, Terraye M. Starr, Moua Yang,Information Technology SpecialistsMMWR Editorial BoardTimothy F. Jones, MD, ChairmanMichelle E. Bonds, MBAM atthew L. Boulton, MD, MPHC arolyn Brooks, ScD, MA Jay C.

4 Butler, MD Virginia A. Caine, MD Katherine Lyon Daniel, PhD Jonathan E. Fielding, MD, MPH, MBAD avid W. Fleming, MD William E. Halperin, MD, DrPH, MPHJ ewel Mullen, MD, MPH, MPAJeff Niederdeppe, PhDPatricia Quinlisk, MD, MPH Patrick L. Remington, MD, MPH Carlos Roig, MS, MAWilliam Schaffner, MD Morgan Bobb Swanson, BSCONTENTSI ntroduction ..1 Methods ..2 Background ..3 Meningococcal Vaccines ..6 Evaluation of Efficacy of Meningococcal Vaccines ..7 Serogroups A, C, W, and Y Meningococcal Vaccines ..7 Serogroup B Meningococcal Vaccines ..15 Vaccine Administration ..20 Recommendations for Use of Meningococcal Vaccines.

5 20 Future Directions in Meningococcal Vaccination ..23 References ..24 CDC Adoption of ACIP Recommendations for MMWR Recommendations and Reports, MMWR Policy Notes, and Immunization Schedules (Child/Adolescent, Adult) Recommendations for routine use of vaccines for children, adolescents, and adults are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of CDC on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of the United States.

6 Recommendations for routine use of vaccines for children and adolescents are harmonized to the greatest extent possible with Recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Nurse-Midwives (ACNM). Recommendations for routine use of vaccines for adults are harmonized with Recommendations of the American College of Physicians (ACP), AAFP, ACOG, and ACNM. ACIP Recommendations approved by the CDC Director become agency guidelines on the date published in the Morbidity and Mortality Weekly Report (MMWR).

7 Additional information is available at and ReportsMMWR / September 25, 2020 / Vol. 69 / No. 9 1US Department of Health and Human Services/Centers for disease control and PreventionMeningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 Sarah A. Mbaeyi, MD1; Catherine H. Bozio, PhD1; Jonathan Duffy, MD2; Lorry G. Rubin, MD3; Susan Hariri, PhD1; David S. Stephens, MD4; Jessica R. MacNeil, MPH51 Division of Bacterial Diseases, National center for Immunization and Respiratory Diseases, CDC; 2 Immunization Safety Office, National center for Emerging and Zoonotic Infectious Diseases, CDC; 3 Steven and Alexandra Cohen Children s Medical center of New York, New Hyde Park, New York, and Hofstra North Shore LIJ School of Medicine, Hempstead, New York; 4 Emory University School of Medicine, Atlanta, Georgia.

8 5 Office of the Director, National center for Immunization and Respiratory Diseases, CDCS ummaryThis report compiles and summarizes all Recommendations from CDC s Advisory Committee on Immunization Practices (ACIP) for use of Meningococcal vaccines in the United States. As a comprehensive summary and update of previously published Recommendations , it replaces all previously published reports and policy notes. This report also contains new Recommendations for administration of booster doses of serogroup B Meningococcal (MenB) vaccine for persons at increased risk for serogroup B Meningococcal disease .

9 These guidelines will be updated as needed on the basis of availability of new data or licensure of new Meningococcal recommends routine vaccination with a quadrivalent Meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination with MenACWY for persons aged 2 months at increased risk for Meningococcal disease caused by serogroups A, C, W, or Y, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor ( , eculizumab [Soliris] or ravulizumab [Ultomiris]); persons who have anatomic or functional asplenia; persons with human immunodeficiency virus infection; microbiologists routinely exposed to isolates of Neisseria meningitidis.

10 Persons identified to be at increased risk because of a Meningococcal disease outbreak caused by serogroups A, C, W, or Y; persons who travel to or live in areas in which Meningococcal disease is hyperendemic or epidemic; unvaccinated or incompletely vaccinated first-year college students living in residence halls; and military recruits. ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased addition, ACIP recommends routine use of MenB vaccine series among persons aged 10 years who are at increased risk for serogroup B Meningococcal disease , including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor; persons who have anatomic or functional asplenia; microbiologists who are routinely exposed to isolates of N.